. Using various strategies to block neutrophil recruitment to the pre-metastatic site, we demonstrate that neutrophils specifically support metastatic initiation. Importantly, we find that neutrophil-derived leukotrienes aid the colonization of distant tissues by selectively expanding the sub-pool of cancer cells that retain high tumorigenic potential. Genetic or pharmacological inhibition of the leukotriene-generating enzyme arachidonate 5-lipoxygenase (Alox5) abrogates neutrophil pro-metastatic activity and consequently reduces metastasis. Our results reveal the efficacy of using targeted therapy against a specific tumour microenvironment component and indicate that neutrophil Alox5 inhibition may limit metastatic progression.
. Cancer cells within a tumour are heterogeneous and retain different tumorigenic potentials. Nonetheless, metastasis-initiating cells (MICs) depend on a favourable microenvironment to grow efficiently at the distant site [8] [9] [10] . We therefore reasoned that an altered presence of leukocytes within distant tissues of tumour-bearing hosts might influence specific subsets of disseminating cancer cells. We investigated this hypothesis using the lung metastatic MMTV-polyoma middle T antigen (PyMT) mammary tumour mouse model, which allows monitoring of the cell subpopulation functionally defined by a higher metastasis initiation ability (CD24 +
CD90
+ MICs) 8 . In accordance with previous reports 11 , we found CD11b
+

Ly6G
+ neutrophils to be systemically mobilized in MMTV-PyMT + tumour-bearing mice and, despite their low frequency within the primary tumour microenvironment, they were the main immune component that increased in metastatic lungs ( Fig. 1a and Extended Data Fig. 1a-l) . Importantly, CD11b
+
Ly6G
+ cells accumulated in the lung before cancer cells infiltrated the tissue (pre-metastatic lung) and their numbers increased during metastatic progression (metastatic lung) (Fig. 1a, b) . We addressed the functional relevance of high CD11b + Ly6G + neutrophil numbers by analysing the metastatic progression of MMTV-PyMT + tumour-bearing mice in a neutropenic granulocyte colony-stimulating factor (Gcsf)-null background. Mice deficient in G-CSF expression developing mammary tumours failed to accumulate neutrophils in the lungs ( Fig. 1d and Extended Data Fig. 2a) . Notably, genetic neutropenia resulted in a robust reduction of spontaneous lung metastasis, despite not affecting primary tumour growth (Fig. 1e, g and Extended Data Fig. 2b ). No differences in lung macrophages compared with wild-type mice were detected (Extended Data Fig. 2c ). Lack of G-CSF expression by cancer cells altered neither lung neutrophil accumulation nor metastasis (Extended Data Fig. 2d ). In an alternative genetic strategy for neutrophil depletion, we crossed MMTV-PyMT + mice with neutrophil elastase (Ela2)-Cre and with ROSA-Flox-STOP-Flox diphtheria toxin (DTA) mice. Here, neutrophil-specific Cre expression led to DTA-mediated reduction of lung neutrophils in tumour-bearing mice, without altering lung macrophages and circulating myeloid cells or activating bone marrow natural killer (NK) and cytotoxic T cells (Extended Data Fig. 2e , f, h-j). Importantly, metastatic progression was impaired in MMTV-PyMT + -Ela2-Cre-DTA + mice without affecting primary tumour growth ( Fig. 1f and Extended Data Fig. 2f, g ).
Since lung neutrophil increase precedes cancer cell infiltration (Fig. 1b) , we focused on the CD11b + Ly6G + cells accumulating in the early phase of lung colonization. We established mammary gland tumours by orthotopic transplantation to synchronize tumour growth, distant neutrophil accumulation and metastatic progression (Extended Data Fig. 3a) . The comparison of tumour-induced CD11b
+
Ly6G
+ cells and CD11b + Ly6G + neutrophils from healthy lungs revealed minor variations, as messenger RNA expression of only two of seven tested neutrophil-secreted factors showed changes (Extended Data Fig. 3b ). Tumour-mobilized lung neutrophils appeared morphologically mature (Fig. 1c ) and the upregulation of CD31 suggests increased lung infiltration 12 (Extended Data Fig. 3b ). Together, these data indicate that, at this time point, tumour-induced CD11b + Ly6G + cells in the lung are mature neutrophils similar to the ones found in healthy lungs. As neutrophils in the tumour context are reported to act as myeloidderived suppressor cells 13 , we investigated the presence of an anticancer immune environment within the pre-metastatic lung of immunecompetent mice. We used anti-Ly6G blocking antibody to deplete neutrophils during the pre-metastatic stage (Extended Data Fig. 4a ). No significant differences were found in the frequencies and activation of various immune components as a consequence of neutrophil depletion, in particular in cytotoxic T and NK cells (Extended Data Figs 4b-o and 5a-i). To explore further the functional contribution of lung neutrophils to metastasis independently of potential immunosuppression, we performed time-controlled neutrophil depletion with anti-Ly6G antibody in immune-compromised mice (Rag1-null) harbouring primary tumours. Remarkably, pre-metastatic neutrophil depletion during metastatic colonization caused a decrease of spontaneous metastasis ( Fig. 1h-j, l) . Concomitantly, lungs of the same mice were synchronously seeded with cancer cells isolated from MMTV-PyMT + actingreen fluorescent protein (GFP) tumours by intravenous injection to initiate lung colonization (Fig. 1h) . Notably, GFP + cancer cells colonizing neutrophil-depleted lungs were significantly reduced, revealing the relevance of lung neutrophils specifically during metastatic initiation (Fig. 1k, l) . No alterations were found in the extravasation efficiency of labelled cancer cells (data not shown). Although we cannot exclude a contribution of other cells to a favourable pre-metastatic environment 5-7 , such as monocytes 14 , these results reveal that the breasttumour-induced systemic accumulation of neutrophils coincidentally acts as a pre-metastatic niche in tissue targeted for metastatic dissemination.
Next, we investigated a potential direct effect of neutrophil-secreted factors on tumour cells. Pre-metastatic lung neutrophils (Extended Data Fig. 6a, b) were used to condition cell culture medium for 14 h (LuN medium). Primary MMTV-PyMT tumour cells cultured in LuN medium in non-adherent culture showed enhanced sphere growth (Fig. 2a, b) . Furthermore, short-term exposure to LuN medium in adherent culture boosted the tumorigenic potential of cancer cells in vivo and in vitro (Fig. 2c, d and Extended Data Fig. 6c, d ). Importantly, short-term culture in LuN medium also increased the metastatic initiation potential of total cancer cells (Fig. 2e, f) .
Cancer cells are also heterogeneous when disseminated into the circulation 15 and might respond differently to environmental stimulations 16 . We therefore probed whether neutrophil-secreted factors influence the relative amount of highly metastatic cells. We monitored the previously described MIC population (CD24
8 after exposing tumour cells seeded into the lung to either LuN medium or freshly isolated pre-metastatic lung neutrophils (Fig. 2g) . Notably, both settings induced a doubling of MIC frequencies among the total cancer cell population (Fig. 2h, i and Extended Data Fig. 6e-h ) and partially increased metastatic growth (Extended Data Fig. 6i-k) . Collectively, we observe that neutrophil-derived factors alter the heterogeneity of cancer cells favouring MICs and lead to increased metastatic competence of total cancer cells (Fig. 2j) .
We aimed to identify neutrophil-secreted factors mediating this activity. LuN medium contains many factors (data not shown) including CCL2, MMP9, interleukin (IL)-6 and IL-1 that might alter inflammatory responses and increase pro-tumorigenic behaviour [17] [18] [19] . Various cells in the tumour microenvironment can secrete these mediators, 
(e) and MMTV-PyMT + control (n = 14) or MMTV-PyMT + Ela2-Cre-DTA + (n = 6) mice (f). g, Representative H&E-stained sections of lung. Scale bar, 500 μm. h, Experimental setup for neutrophil depletion. i, Flow cytometric lung neutrophil quantification (n = 4 (tumour-free), n = 12 (IgG tumour), n = 11 (Ly6G tumour)). j, k, Spontaneous (n = 8 per group) (j) and experimental metastasis (n = 12 per group) (k). Lin, CD45,CD31,TER119. l, Histological GFP-stained lung sections including close-up on spontaneous (arrow) and experimental metastases (brown). Scale bar, 500 μm. Statistical analysis by two-sided t-test. Data are represented as mean ± standard error of the mean (s.e.m.). *P < 0.05, **P < 0.01, ***P < 0.001. so we concentrated on specific innate leukocyte-derived factors. We detected high levels of the lipids leukotriene B4 (LTB4) and cysteinyl leukotrienes C4, D4 and E4 (LTC/D/E4), products of the Alox5 enzyme 20 (Fig. 3a-c) . Importantly, direct leukotriene (LT) stimulation boosted sphere formation and a short 3-day LT exposure of total cancer cells enhanced their tumour initiation potential (Extended Data Fig. 7a-c) . Notably, cells expressing LT receptors (LTRs; LTB4 receptor 2 (BLT2) and LTC/E/D4 receptor 2 (CysLT2)) 21,22 appeared to be enriched among MICs within total MMTV-PyMT cancer cells as well as among other known tumorigenic subpopulations of breast cancer cell lines [23] [24] [25] (Fig. 3d , e and Extended Data Fig. 7d-i) . Indeed, LTRs themselves identified MMTV-PyMT cancer cells with high sphere and tumour formation abilities (Extended Data Fig. 7j-l) .
In accordance with LTR expression on MICs, we found that 3-day LT stimulation of MMTV-PyMT tumour cells in vitro increased MIC frequency and metastatic initiation capacity in vivo (Fig. 3f-h ), similar to neutrophil-derived mediators (Fig. 2e-j) . LT stimulation also enriched the CD49f high sub-pool among 4T1 cells (Extended Data  Fig. 8b ). Other cells such as macrophages and eosinophils respond to LTs, but no broader inflammatory reaction was detected at this stage To confirm the functional relevance of LTs in vivo, we took advantage of an Alox5-null mouse model (Fig. 3c) . We generated bone marrow chimaeric mice in which Alox5 is genetically depleted in the radiosensitive immune cell compartment. Bone marrow Alox5-null mice grafted with MMTV-PyMT cells showed unaltered primary tumour growth and neutrophil lung accumulation ( Fig. 4a and Extended Data Fig. 9a-d ), yet the efficiency of spontaneous e-k, Spontaneous (e) and experimental (f, i, k) metastasis of MMTVPyMT cells (n = 9 (PyMT DMSO), n = 7 (PyMT Zil)) (e-g), 4T1 cells
Representative histological lung sections GFP stained with close-up on spontaneous (arrows) and experimental metastases (brown) (g) or H&E stained (h, k). Scale bars, 500 μm. l-o, BLT2 (l, m) or CysLT2 (n, o) staining (brown) of human breast cancer and matched lymph node (LN) metastases (n ≥ 30 per group). Quantification of staining intensity and frequency (l, n) and representative images (m, o). Scale bar, 50 μm. Statistical analysis by two-sided t-test (b, e, f, i), Mann-Whitney test (c) and one-sided t-test (k). Data are represented as mean ± s.e.m. NS, not significant, *P < 0.05, ***P < 0.001. metastasis was reduced (Fig. 4b) . Next, we generated LT-deficient LuN (LuN-Alox5ko) medium from Alox5-null pre-metastatic lung neutrophils. Importantly, LuN-Alox5ko medium failed to boost the metastatic potential of luciferase-expressing MMTV-PyMT cells after 3-day pre-treatment (Figs 2c, 4c and Extended Data Fig. 9e, f) . Taken together, these data confirm Alox5 products to be crucial for neutrophil pro-metastatic activity. LTs are important mediators during inflammatory asthma and are targeted by the specific Alox5 inhibitor zileuton (Zil) 27 . We explored Zil-mediated inhibition of LT synthesis to treat metastatic breast cancer in mice. Zil blocked LT production in vivo, detected by decreased LTB4 levels in LuN medium (LuN-Zil) (Extended Data Fig. 10a, b) and, consequently, LuN-Zil medium failed to enhance metastasis (Fig. 4c) . Importantly, in a therapeutic setting (Fig. 4d) , treatment of MMTVPyMT tumour-harbouring mice with Zil reduced spontaneous metastasis (Fig. 4e, g ), without altering primary tumours or lung neutrophil levels (Extended Data Fig. 10c, d) . Additionally, the colonization capacity of GFP + MMTV-PyMT cancer cells seeded into lungs of Zil-treated mice was reduced (Fig. 4f, g ). We confirmed that metastatic cancer cells showed reduced proliferation very early after infiltrating Zil-treated lungs (Extended Data Fig. 10e ). Taken together, these data represent a potential therapeutic approach to target this novel LT/Alox5-dependent neutrophil pro-metastatic activity.
Importantly, similar results on the efficacy of Zil treatment in limiting metastatic progression were confirmed in two metastatic breast cancer cell lines, mouse 4T1 cells and human MDA-MB-231 cells (Fig. 4h-k and Extended Data Fig. 10f-i ). As Zil treatment had no effect on long-term primary tumour growth in vivo or on cancer cell behaviour in vitro (Extended Data Fig. 10j-m) , we exclude involvement of Alox5 products in a cancer-cell autocrine loop.
Clinical data correlating high neutrophil levels with poorer prognosis 28, 29 , together with detected LTR expression in human metastatic ductal and lobular breast carcinoma and their lymph-node metastases ( Fig. 4l-o) , suggests that a similar neutrophil pro-metastatic mechanism might boost human breast cancer progression to the lung.
We have identified a novel LT/Alox5-dependent pro-metastatic activity of neutrophils supporting highly metastatic cells that can be targeted by Zil, offering hope for new cancer therapeutics.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.
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Mouse strains. The MMTV-PyMT mice were a gift from E. Sahai, MMTV-PyMT actin-GFP (mice expressing green fluorescent protein under the control of the actin promoter), Gcsf-null and Rag1-null mice were a gift from J. Huelsken, MMTVPyMT actin-luciferase (mice expressing firefly luciferase under the control of the actin promoter) transgenic line was a gift from D. Bonnet, Rosa26R-eGFP-DTA mice were a gift from C. Reis e Sousa. Ela2-Cre knock-in mice and Alox5-null mice were purchased from European Mouse Mutant Archive (EMMA) and Jackson Laboratory, respectively. All mouse strains have been described previously [30] [31] [32] [33] [34] [35] [36] [37] . All strains of mice were in >10 generations FVB/N and/or C57BL/6 background except Gcsf-null, Ela2-Cre and Rosa26R-eGFP-DTA mice that were used in mixed background with littermate controls. Female mice were used between 6-9 weeks of age, except spontaneous cancer models. Breeding and all animal procedures were performed in accordance with UK Home Office regulations under project license PPL/80/2531. Mouse experiments. Where applicable, mice were anaesthetized with IsoFlo (isoflurane, Abbott Animal Health) and temporally treated with the analgesics Vetergesic (Alstoe Animal Health) and/or Rimadyl (Pfizer Animal Health). For tumour studies under the project licence PPL/80/2531, the overruling determinant was animal welfare. The National Cancer Research Institute (NCRI) Guidelines for the Welfare and Use of Animals in Cancer Research were followed. When assessing primary tumour growth, a mean diameter of 1.5 cm for single tumours was not exceeded. However, for multifocal disease such as MMTV-PyMT cancer, provided that there were no additional adverse welfare consequences for the animal, the total superficial tumour burden was allowed to exceed these dimensions when essential for the achievement of the scientific objective, namely spontaneous metastasis. Mice were monitored daily for signs of adverse effects. The source data for primary tumour growth are in Supplementary Fig. 3 . Tumour cell transplantations and induction of experimental metastasis. FVB/N wild-type mice were used for MMTV-PyMT tumour cell transplantations to isolate lung neutrophils. Rag1-null mice were used when using human or mouse GFP or luciferase-expressing tumour cells. 
MMTV-PyMT
+ mice that spontaneously developed a primary tumour and had visible lung metastasis were used to determine immune cell presence in the lung and neutrophil presence in other organs together with tumour-free littermate controls. For determination of timing and dynamics of lung infiltration by neutrophils and cancer cells, MMTV-PyMT + mice harbouring 1.5-2 g spontaneously developed tumours were used. Neutrophil infiltration was quantified by flow cytometry and histological staining of lung sections for S100A9 and cancer cell presence by examination of six histological lung sections (100 μm apart) for PyMT staining to confirm the pre-metastatic state. The timing of neutrophil infiltration into the pre-metastatic lung before cancer cells was confirmed in FVB/N wild-type mice carrying two primary tumours originating from orthotopic injection of primary MMTV-PyMT cancer cells and used for analysis (daily treated with anti-Ly6G or control IgG antibody starting 24 h before tumour cell implantation).
Analysis of MMTV-PyMT
+ G-CSF and MMTV-PyMT + Ela2-DTA mice. Mice were culled and analysed about 6 weeks after spontaneous primary tumour onset; no differences were observed in tumour onset among the different genotypes. Treatments with neutrophil-blocking antibody anti-Ly6G or Zil. Rat anti-Ly6G antibody 38, 39 (12.5 μg per mouse; clone 1A8 from BioXcell) or rat IgG isotype control (provided by the Cell Services Unit of The Crick Institute) in 100 μl saline were administered daily via intraperitoneal injection. Zil (LKT Laboratories) dissolved in DMSO (Sigma) or DMSO alone was fed to mice by pipetting on the back of the tongue once a day at a dosage of 100 μg Zil per g mouse weight.
Lung colonization by cancer cells after neutrophil depletion or Zil treatment.
Rag1-null mice were orthotopically transplanted with unlabelled mammary tumour cells 4 weeks before labelled tumour cell injection via the tail vein (MMTVPyMT and 4T1 10 5 cells, MDA-MB-231 10 6 cells). Anti-Ly6G or Zil treatment for 2 weeks (except 4T1, 10 days) started 1 day before intravenous injection of cancer cells. Then, total primary tumour burden, neutrophil presence in the lung, spontaneous lung metastasis incidence from the transplanted primary tumour and/or experimentally induced lung metastasis originating from the intravenously injected cancer cells was analysed.
Of note, exclusively experimental metastasis are present in lung harbouring MDA-MB-231 cells, while predominantly spontaneous metastases are visible in lung harbouring 4T1 cells due to the high spontaneous metastasis rate of primary 4T1 tumours. Only GFP + experimental metastasis induced by cancer cell injection was quantified in these experiments. Tumour/metastasis initiation potential assay in vivo. Primary MMTV-PyMT cells were either cell sorted for BLT2 and/or CysLT2 presence or absence, or treated for 3 days on collagen-coated dishes with either neutrophil-conditioned medium or LTB4 and LTC/D/E4. Subsequently, 10 3 -10 4 cells were orthotopically transplanted into the mammary gland or 10 6 cells injected via the tail vein into Rag1-null mice and mammary tumour growth or lung metastasis incidence analysed about 3 weeks thereafter. MICs or metastasis quantification after neutrophil/LuN injection. To analyse total cancer cells at early stages, Rag1-null mice were injected with 0.5-1 × 10 6 MMTV-PyMT actin-GFP cells via the tail vein followed 12 h later by intravenous injection of 25 × 10 6 neutrophils (freshly isolated from MMTV-PyMT tumour-transplanted mice) or 12, 24 and 36 h later by intravenous injection of 200 μl lung neutrophil-conditioned or control sphere medium (described later). Cancer cells in the lung were analysed 3 days after the initial tumour cell injection for frequencies of CD90 + MICs among GFP + CD24 + (non-MIC) cancer cells. For determination of effects of neutrophils or neutrophilconditioned medium on metastatic burden, Rag1-null mice were intravenously injected with 1-10 × 10 5 MMTV-PyMT actin-GFP or actin-luciferase cells followed immediately, 2 and 4 days later, by injection of 25 × 10 6 neutrophils or 3-5 times every 12 h by injection of 200 μl lung neutrophil-conditioned medium. Metastatic burden was determined by flow cytometric analysis of GFP + cancer cells 1 week or bioluminescence imaging of luciferase + cancer cells 2-4 weeks thereafter, respectively.
Analysis of functional effects of G-CSF deficiency in MMTV-PyMT cancer cells.
Rag1-null mice were transplanted with 10 6 Gcsf-null primary MMTV-PyMT cancer cells into two mammary glands and tumour growth, spontaneous metastatic incidence and neutrophil presence in the lung were analysed 4 weeks thereafter. Bone marrow transplantation and semi-quantitative PCR. C57BL/6 wild-type mice were lethally irradiated (dosage: 2× 600 rad, 4 h apart) and 24 h later injected via the tail vein with 2 × 10 6 bone marrow cells freshly isolated from C57BL/6 or Alox5-null donor mice. Bone marrow chimaeric mice were orthotopically transplanted with 10 6 MMTV-PyMT cells into the fourth mammary fat pad on both sides 8 weeks after bone marrow reconstitution and primary tumour size, neutrophil infiltration into the lung and lung metastasis were analysed 6 weeks later. Chimaeric mice were generated in a pure C57BL/6 background, therefore MMTV-PyMT cells from the same background were used to generate primary tumours. In this lower tumorigenic background, metastasis only occurs in about 50% of the mice. No alteration in this penetrance was observed between wildtype and Alox5-null bone marrow chimaeric mice. Figure 4b quantifies animals harbouring metastatic disease.
Percentage of bone marrow reconstitution was calculated by isolating total DNA from bone marrow of chimaeras and semi-quantitative PCR with a calibration curve from 100% wild-type DNA mixed at defined ratios with 100% Alox5-null DNA. PCR was performed using Redtag reagents (Sigma) (primers are listed in Supplementary Information) and 25 amplification cycles before loading an agarose gel. Ratio between wild-type and Alox5-null band was calculated for every mouse and percentage chimaerism was determined by comparison with calibration curve. Chimaerism was consistently between 80 and 96%. Tumour and metastasis burden evaluation. See Supplementary Methods. In vivo luciferase-activity detection. Mice inoculated with actin-luciferaseexpressing MMTV-PyMT cells were shaved around the chest area and injected with 3 mg XenoLight d-luciferin potassium salt (PerkinElmer) in PBS into the peritoneum 5 min before imaging for at least 45 min using the IVIS Spectrum Preclinical In vivo Imaging System (PerkinElmer). The maximum bioluminescence intensity signal for the lung of every mouse was determined using Living Image 4.3.1 software. Tissue staining, immunohistochemistry and light microscopy. Mouse lung tissue was fixed in 4% paraformaldehyde in PBS for 24 h and embedded in paraffin blocks. Four-micrometre sections were stained. The breast cancer tissue array paired with metastatic tumours, 96 samples (1.5 mm), was purchased from Abcam (ab178118). H&E staining was performed according to standard procedures.
For immunohistochemistry, either secondary horseradish peroxidase (HRP)-conjugated antibodies were used in combination with DAP Peroxidase substrate or the VECTASTAIN ABC kit (all Vector Laboratories) according to the manufacturer's instructions. Specific primary antibodies were used (see Supplementary Information), visualization of cell nuclei was performed with haematoxylin and analysis employed the Nikon Eclipse 90i light microscope and NIS-elements software. Scoring of LTR expression in breast cancer tissue and lymph node metastasis. See Supplementary Methods. Tissue digestion for cell isolation or analysis. MMTV-PyMT cell isolation was described in detail previously 8 . In brief, primary MMTV-PyMT tumours, liver, spleen and lung were dissected, minced, and digested with Liberase (Roche) and DNaseI (Sigma) in HBSS and passed through a 100 μm cell strainer. Some tumour cells were used for cell culture at this point. Bone marrow cells were isolated by crushing the femur and tibia and blood collected via bleeding from the tail vein with heparin (Sigma) as a coagulant. For flow cytometric analysis or further purification, single-cell suspensions of tumour, liver, spleen, lung, bone marrow and blood were subjected to hypotonic lysis (Red Blood Cell Lysis Solution, Miltenyi) to remove erythrocytes and washed with 1× PBS/2 mM EDTA/0.5% BSA. Flow cytometry and cell sorting. Prepared single-cell suspensions of mouse tissues and in vitro treated cancer cells were incubated with mouse FcR Blocking Reagent (Miltenyi) followed by incubation with (a combination) of specific pre-labelled antibodies or in combination with fluorescently labelled secondary antibodies (Invitrogen) (see Supplementary Information). Dead cells were stained with 4′ ,6-diamidino-2-phenylindole (DAPI) or propidium iodide (PI; both Sigma). The LSRFortessa cell analyser running FACSDiva software (BD Biosciences) and FlowJo software was used. Tumour cells were flow-sorted using the Influx cell sorter running FACS Sortware sorter software (BD Biosciences). MMTV-PyMT cells were used in experiments immediately after sorting and sorted 4T1 cells cultured in adherent conditions for 3 days before western blot analysis. Neutrophil isolation and neutrophil-conditioned medium. Freshly isolated lung cells from wild-type mice orthotopically transplanted with MMTV-PyMT tumours were incubated with mouse FcR Blocking Reagent (Miltenyi), APC-coupled antiLy6G (clone 1A8) antibody (BD Bioscience) followed by incubation with magnetic anti-APC microbeads (Miltenyi). Magnetically labelled neutrophils were isolated using LS columns (Miltenyi) according to the manufacturer's instructions. Neutrophil purity and viability was measured by flow cytometry. Some isolated Ly6G + cells were smeared onto a glass slide and air-dried overnight followed by H&E staining to evaluate cell morphology. Remaining neutrophils were kept in sphere medium at a concentration of 10 6 neutrophils per 150 μl medium for 14 h to allow conditioning. Neutrophils and cell debris were removed by centrifugation and conditioned medium occasionally snap-frozen before use. Cell culture and in vitro cancer cell treatments. All used cell lines were provided by the Cell Services Unit of The Crick Institute, which routinely tests for Mycoplasma contamination and were not further authenticated in our laboratory. Cell lines were cultured in DMEM medium supplemented with 10% fetal bovine serum (DMEM/FCS, both Invitrogen). Freshly isolated MMTV-PyMT cells were cultured overnight on PureCol collagen (Advanced Biomatrix)-coated dishes in growth medium DMEM/F12 with 2% FBS, 20 ng ml −1 EGF (Invitrogen) and 10 μg ml −1 insulin (Sigma) before use in experiments. All in vitro and in vivo experiments involving primary MMTV-PyMT cells were performed with at least two primary tumour cell preparations from different spontaneous MMTV-PyMT + mice. Unless otherwise specified, each in vitro and in vivo experiment was performed with a different tumour cell preparation.
Primary MMTV-PyMT cells were cultured in sphere medium on collagencoated dishes, 4T1 and MDA-MB-231 cells in DMEM/FCS on uncoated dishes or in non-attachment conditions for the indicated periods of time under presence of (as indicated for every experiment): control sphere medium, neutrophilconditioned medium, 100% ethanol control (EtOH, Sigma), DMSO control, 1 μM LTB4, 100 nM LTC/D/E4 (Cysteinyl Leukotriene HPLC Mixture I), 3 μM BLT2 inhibitor LY255283, 0.3 μM CysLT2 inhibitor BAY-u9773 (all Cayman Chemical), 1 μM Zil and/or 1 nM pan-MEK inhibitor PD0325901 (provided by J. Downwards) followed by further tests or analysis. Sphere formation assay. The sphere formation assay was described previously 8 . In brief, 10 4 total MMTV-PyMT or flow-sorted cells per well were plated in ultra-low-attachment 96-well plates (Costar) in 100 μl sphere medium DMEM/ F12 supplemented with B-27, 20 ng ml −1 EGF, 20 ng ml −1 FGF (all Invitrogen) and 4 μg ml −1 heparin (Sigma) or neutrophil-conditioned medium. After 7-10 days, if not otherwise indicated, all formed spheres were quantified from images taken with the inverted Leica DM IRBE light and fluorescence microscope. The area of the plane passing through the sphere centre was measured for every sphere (sphere size) using ImageJ software and the areas of all formed spheres were summed up. The obtained number was divided by total number of plated cells. This value represents the sphere formation index (SFI) per cell for every experimental group. Freshly isolated MMTV-PyMT cells were either only treated for 3 days in adherent conditions before sphere assay or directly treated during the sphere assay with neutrophil-conditioned medium or LTB4 and/or LTC/D/E4 or Zil, as indicated. When cells were passaged, cells were quantified by cell counting and re-plated in equal numbers per well for the next passage approximately every 7 to 10 days. In vitro and in vivo BrdU incorporation assay. Rag1-null mice carrying MMTVPyMT tumours were treated daily for 3 days with Zil and intravenously injected with 10 5 GFP-expressing MMTV-PyMT cancer cells. BrdU (1 mg per mouse) was intraperitoneally injected 18 h after GFP + cancer cells and lungs were harvested and digested 6 h later. In vitro 3-day MMTV-PyMT or 4T1 cells treated as indicated in adherent conditions were pulsed with 30 μM BrdU (Sigma) for 3 h and harvested. Cells were incubated with fluorescently labelled anti-CD24 and/or anti-CD90.1 antibody if indicated. BrdU Flow Kit (BD Bioscience) was used for staining followed by analysis by flow cytometry. In vitro quantification of primary MICs and sub-pools of cancer cell lines. Primary MMTV-PyMT cells were cultured on collagen-coated dishes for 3 days supplemented with either LTB4 and LTC/D/E4 or Zil followed by incubation with fluorescently labelled anti-CD90.1 and anti-CD24 antibodies and analysis by flow cytometry. 4T1 and MDA-MB-231 cell lines were cultured in DMEM/ FCS supplemented with LTB4 and LTC/D/E4 for 3 days in adherent conditions followed by either staining with fluorescently labelled anti-CD49f, anti-BLT2, antiCysLT2 and/or anti-CD44 antibodies or using the ALDEFLUOR kit (StemCell Technologies) according to the manufacturer's instructions and analysed by flow cytometry. RNA expression/quantitative real-time PCR. Neutrophils were freshly isolated from the lungs of wild-type or MMTV-PyMT tumour-bearing mice. RNA isolation was performed using MagMAX-96 Total RNA Isolation Kit and cDNA synthesis using SuperScript III Reverse Transcriptase. Quantitative PCR reactions were performed using EXPRESS SYBR GreenER reagents with the Applied Biosystems 7500 Fast Real-Time PCR System (all Invitrogen) and specific primers (see Supplementary Information). Enzyme immunoassay and parameter enzyme-linked immunosorbent assay. Ethanol was used to precipitate protein from cell culture medium before analysis using either the enzyme immunoassays (EIAs) LTC/D/E4 Biotrak EIA System (Amersham) or the LTB4 EIA Kit (Cayman Chemical) according to the manufacturer's instructions. Western blot analysis and protein detection. Primary MMTV-PyMT cells grown on collagen-coated dishes were cultured overnight in DMEM/F12 with B-27, and 4 μg ml −1 heparin (Sigma) before treatment with 1 μM LTB4 or 100 nM LTC/D/E4. Unsorted or sorted LTR-reduced 4T1 cells were stimulated with LTB4, LTC/D/E4, BLT2 inhibitor LY255283 and/or CysLT2 inhibitor BAY-u9773 as indicated. Cells were washed and protein isolated using RIPA buffer (25 mM Tris-hydrogen chloride pH 7.6, 50 mM sodium chloride, 1% NP-40, 1% sodium deoxycholate, 0.1% soduim dodecyl sulfate) freshly supplemented with 1 μM sodium pyrophosphate, 1 μM B-glycerophosphate, 1 μM sodium vanadiumoxide, 1 μM sodium fluoride, 1 μM sodium molybdate (all Sigma) and cOmplete ULTRA Tablets (Roche), and processed by standard western blot techniques. Membranes were blocked with 5%BSA in PBS with 0.5% Tween-20 (Sigma) and incubated with specific primary antibodies (see Supplementary Information). ECL Western Blotting System including secondary antibodies and Hyperfilm ECL (both Amersham) were used. Protein lysates of 3 h LTB4-stimulated MDA-MB-231 cells were analysed using the Proteome Profiler Human Phospho-Kinase Array Kit (R&D systems) according to the manufacturer's instructions. Western blot quantification was performed on scanned films using ImageJ software. Statistical analysis. Data analyses used GraphPad Prism version 7. The data are presented as mean ± standard error of the mean, individual values, 'scatter plot with Tukey box and whiskers' and/or 'scatter plot with column bar' graphs and were analysed using Student's t-tests (paired or unpaired according to the experimental setting), Mann-Whitney tests, one-sample t-tests and two-way ANOVA as indicated in the legends. Data were pooled from at least two experiments, except Fig. 4c , i, k and Extended Data Figs 2d, 4d-m, 5a, b, f, h, 6k, 10e, in which data are at least biological triplicates generated in parallel. Two-way ANOVA was performed when the control groups between experiments were significantly different. Western blot in Extended Data Fig. 8i , k, the proteome profiler dot blot in Extended Data Fig. 8d and BrdU incorporation of 4T1 cells in Extended Data Fig. 10k were performed once. Extended Data Fig. 3b (mRNA expression) compares biological triplicates of the pre-metastatic to a representative control (wild-type) value. The experiments were not randomized and there was no blinding as animals or samples were marked. No statistical methods were used to predetermine sample sizes. Sample sizes were based on previous experience with the models 8, 14 . n values represent biological replicates, with the exception of the sphere assays, for which both technical and biological replicates are shown.
Differences were considered significant when P < 0.05 and are indicated as NS, not significant, *P < 0.05, **P < 0.01, ***P < 0.001. + Ly6G + neutrophils in the bone marrow (n = 6 (wild type), n = 5 (MMTV-PyMT + )) (a), liver (n = 4 (wild type), n = 5 (MMTV-PyMT + )) (b) and spleen (n = 6 (wild type), n = 5 (MMTV-PyMT + )) (c) of wild-type (WT) and tumour-bearing MMTV-PyMT + mice. d, Quantification of neutrophils in the tumour and metastatic lung of MMTV-PyMT + mice (n = 2 per group), pre-metastatic lung neutrophil levels depicted in Fig. 1a are shown for comparison in dashed lines. Met., metastatic. e-l, Flow cytometric quantification of immune cell frequencies in wild-type and metastatic lungs of MMTV-PyMT + mice (n = 4 (wild type), n = 7 (metastatic) if not otherwise indicated) including CD45
+ total immune cells (e), total CD11b + F4/80 + macrophages (f) (n = 4 (wild type), n = 4 (metastatic)), the CD11b low F4/80 high alveolar macrophage subpopulation (n = 4 (wild type), n = 4 (metastatic)) (g), the CD11b high F4/80 low interstitial macrophage subpopulation (n = 4/WT, n = 4/Met.) (h), CD45 + CD11c + dendritic cells (i), CD45 + CD49b + NK cells (j), CD45 + CD19 + B lymphocytes (k) and CD45 + CD3 + T lymphocytes (l). Statistical analysis by two-sided t-test. Data are represented as mean ± s.e.m. NS, not significant, *P < 0.05, **P < 0.01, ***P < 0.001.
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Extended Data Figure 6 | Neutrophil isolation from the lung of MMTVPyMT + mice and effect of neutrophil-derived factors on tumour formation potential. a, Representative flow cytometric analysis of neutrophil purity after isolation from the pre-metastatic lung compared to total lung tissue. Only neutrophil purity of ≥90% was used for further experiments. b, Neutrophil viability was assessed by flow cytometry for propidium iodide (PI) negativity after isolation (n = 10). c, d, MMTVPyMT cells grown in control or LuN medium for 3 days in adherent conditions were plated in non-attachment conditions followed by sphere quantification at day 10 post-seeding (technical replicate n = 17 (control), n = 21 (LuN) of biological triplicates) (c) or 10 4 cells grafted onto the mammary gland of Rag1-null mice for analysis of tumour formation potential (d). Tumour burden was determined by weighing about 3 weeks after (n = 12 per group), complementary to Fig. 2d . e-h, Flow cytometric quantification of frequencies of total present GFP-labelled MMTV-PyMT cells (e, g) and frequencies of CD24 + CD90 + MICs among total GFPlabelled MMTV-PyMT cells (f, h) in the lung of Rag1-null mice 3 days after intravenous injection of 5 × 10 5 total GFP-labelled MMTV-PyMT cells followed by either three intravenous injections with control or LuN medium (n = 6 (PyMT+ control), n = 8 (PyMT+ LuN)) (e, f) or by one intravenous injection with 25 × 10 6 neutrophils freshly isolated from a pre-metastatic lung (n = 7 (PyMT+ control), n = 8 (PyMT+ neutrophils) (g, h). f, h, Two independent experiments are shown to complement Fig. 2h , i. Exp, experiment. i-k, Experimental setup (i): Rag1-null mice were intravenously injected with 1-10 × 10 5 (j) or 0.5 × 10 6 total GFPlabelled MMTV-PyMT cells (k) followed by either 3-5 intravenous injections with 200 μl control or LuN medium (j) or by 3 intravenous injections with 25 × 10 6 neutrophils (k) freshly isolated from a pre-metastatic lung. Quantification of experimental metastatic incidence by determination of bioluminescence intensity (n = 7 (control), n = 9 (LuN)) (j) or flow cytometric analysis of GFP + cancer cells in the lung (n = 5 (control), n = 4 (neutrophil)) (k) is shown. Statistical analysis by two-sided t-test (c, j, k) and two-way ANOVA (d-h). Data are represented as mean ± s.e.m. NS, not significant, *P < 0.05, **P < 0.01, ***P < 0.001.
